In August, OCRA hosted a listening session with the U.S. Food and Drug Administration (FDA) to better understand the impact of Covid-19 on clinical trial participation.
Watch the full FDA listening session in the video below.
Related Topics
The Overview: July 2025
OCRA Rivkin Family SummeRun Raises Over $320,000 for Research More than 900 participants gathered at Seattle’s Seward Park for the Ovarian Cancer Research Alliance (OCRA) Rivkin Family SummeRun, raising more than … Continued
OCRA’s Advocate’s Corner: July 2025
Written by Chad Ramsey, Vice President, Policy, Ovarian Cancer Research Alliance FY26 Budget & Appropriations Update: Approaching August with Focused Advocacy As Congress advances the FY 2026 appropriations process, gynecologic cancer advocates … Continued
KIRO-TV 7 Seattle (CBS) Spotlights 2025 OCRA Rivkin Family SummeRun and Community
The 2025 OCRA Rivkin Family SummeRun brought together more than 900 participants in Seattle to raise critical funds for ovarian cancer research. KIRO-TV 7 Seattle (CBS) covered the event in … Continued